ScreenerHero

CHRS Coherus Oncology, Inc.

NAS · US · Healthcare · Biotechnology · coherus.com
1.010USD-1.94%Mkt Cap: 156.05M $P/E: —

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting gr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap156.05M USD
Enterprise Value108.01M USD
Revenue (TTM)50.94M USD
Gross Profit28.36M USD
Net Income (TTM)168.02M USD
Revenue/Share0.39 USD
Last Price1.010 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees144
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.63
PEG—
EV/EBITDA-0.72
EV/Revenue2.12
P/S3.12
P/B2.61
EPS (TTM)-1.25
EPS (Forward)-0.63
52W Range
1.0100% of range2.616
52W High2.616 USD
52W Low1.010 USD
Profitability
Gross Margin67.24%
Oper. Margin-225.98%
EBITDA Margin-295.25%
Profit Margin398.43%
ROE275.39%
ROA65.04%
Growth
Revenue Growth39.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.51M USD
CapEx (TTM)—
FCF Margin-314.42%
FCF Yield-102.63%
Net Debt-51.13M USD
Net Debt/EBITDA0.34
Balance Sheet
Debt/Equity0.66
Current Ratio1.77
Quick Ratio1.58
Book Value/Sh0.39 USD
Cash/Share0.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.750 USD
Upside (mean)+667.3%
Target Range4.000 USD – 10.00 USD
4.000+667.3% to mean10.00
# Analysts4
Ownership
Shares Out.154.50M
Float135.60M
Insiders19.12%
Institutions37.46%
Short Interest
Short Ratio21.0d
Short % Float15.24%
Short % Out.14.79%
Shares Short22.85M
Short (prev mo.)24.00M
Technical
SMA 501.314 (-23.2%)
SMA 2001.571 (-35.7%)
Beta0.99
S&P 52W Chg16.45%
Avg Vol (30d)1.38M
Avg Vol (10d)1.69M
Technical Indicators
RSI (14)31.4
MACD-0.0760
MACD Signal-0.0540
MACD Hist.-0.0220
BB Upper1.476 USD
BB Middle1.236 USD
BB Lower0.9954 USD
BB Width38.87%
ATR (14)0.0881 USD
Vol Ratio (20d)0.81x